Quest and Vermillion to launch OVA1 ovarian cancer test in India
This article was originally published in Clinica
The co-developers of the OVA1 ovarian cancer blood test, Quest Diagnostics and Vermillion, are to launch the test in India, its first market outside the US. It should become available there in the second quarter. OVA1 is designed to determine whether a pelvic mass is malignant or benign in women who are about to undergo surgery. This could help determine which physician is most appropriate for removing the mass – gynaecologic oncologists are more experienced than regular gynaecologists at dealing with invasive, malignant tumours.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.